BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21798721)

  • 1. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
    Kemp DE; Karayal ON; Calabrese JR; Sachs GS; Pappadopulos E; Ice KS; Siu CO; Vieta E
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):123-31. PubMed ID: 21798721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.
    Pae CU; Masand PS; Mandel FS; O'Gorman C
    Clin Drug Investig; 2012 Nov; 32(11):747-54. PubMed ID: 23026845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
    Citrome L
    Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
    Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
    Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.
    Bowden CL; Karayal ON; Schwartz JH; Gundapaneni BK; O'Gorman C
    J Affect Disord; 2013 Jan; 144(1-2):171-5. PubMed ID: 22999893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
    Potkin SG; Keck PE; Segal S; Ice K; English P
    J Clin Psychopharmacol; 2005 Aug; 25(4):301-10. PubMed ID: 16012271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.
    Marcus R; Khan A; Rollin L; Morris B; Timko K; Carson W; Sanchez R
    Bipolar Disord; 2011 Mar; 13(2):133-44. PubMed ID: 21443567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
    Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
    CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
    Loebel A; Cucchiaro J; Silva R; Kroger H; Sarma K; Xu J; Calabrese JR
    Am J Psychiatry; 2014 Feb; 171(2):169-77. PubMed ID: 24170221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
    Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.
    Keck PE; Versiani M; Warrington L; Loebel AD; Horne RL
    J Clin Psychiatry; 2009 Jun; 70(6):844-51. PubMed ID: 19573482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
    Kemp DE; De Hert M; Rahman Z; Fyans P; Eudicone JM; Marler SV; Baker RA; Carlson BX
    J Affect Disord; 2013 May; 148(1):84-91. PubMed ID: 23261129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode.
    Yatham LN; Fountoulakis KN; Rahman Z; Ammerman D; Fyans P; Marler SV; Baker RA; Carlson BX
    J Affect Disord; 2013 May; 147(1-3):365-72. PubMed ID: 23290791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
    Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
    Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.